- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06052605
Sunn aldring hos personer med epilepsi-program (HAP-E)
10. juni 2026 oppdatert av: Anny Reyes
Sunn aldring hos mennesker med epilepsi-program (HAP-E): Å lukke gapet i epilepsiomsorgen
Målet med denne kliniske studien er å utvikle og teste et pedagogisk program om demens hos eldre voksne som lever med epilepsi. Hovedspørsmålene den tar sikte på å besvare er:
- Kan det å gi opplæring om sunn aldring, kronisk sykdomshåndtering, demens og modifiserbare livsstilsdemensrisikofaktorer forbedre demenskunnskap og helsekompetanse blant eldre voksne med epilepsi?
- Kan aldringsrelatert utdanning og ressurser forbedre livskvaliteten blant eldre voksne med epilepsi?
Deltakerne vil:
- Fullfør et 12-ukers gruppeutdanningsprogram.
- Fullfør før- og etterprogramevaluering.
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
380
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Anny Reyes, PhD
- Telefonnummer: 216-390-4266
- E-post: REYESA14@ccf.org
Studiesteder
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Cleveland Clinic
-
Ta kontakt med:
- Anny Reyes, PhD
- Telefonnummer: 216-390-4266
- E-post: REYESA14@ccf.org
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inklusjonskriterier:
- Nåværende diagnose av epilepsi satt av en nevrolog, epileptolog eller internist/familielege
- Ferdigheter i engelsk
Ekskluderingskriterier:
- Demens
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Part 1a: Patient Survey
Patients with receive an online survey to identify barriers in accessing geriatric care, target educational topics, and concerns about aging.
Additionally, they will be surveyed on unmet needs in their care, availability of healthcare information and resources related to aging and dementia, and elements of the program most important to them.
|
Patients with receive an online survey to identify barriers in accessing geriatric care, target educational topics, and concerns about aging.
Additionally, they will be surveyed on unmet needs in their care, availability of healthcare information and resources related to aging and dementia, and elements of the program most important to them.
|
|
Annen: Part 1b: Provider Survey
Providers will receive an online survey to identify barriers in accessing geriatric care, target educational topics, and concerns about aging.
|
Providers will receive an online survey to identify barriers in accessing geriatric care, target educational topics, and concerns about aging.
|
|
Eksperimentell: Part 3: Intervention
Participants randomized to this group will receive a 12-week group educational program (either virtual or in-person based on patient preference) providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors.
|
Dette er et 12-ukers gruppeutdanningsprogram som gir opplæring om sunn aldring, behandling av kroniske sykdommer, demens og modifiserbare risikofaktorer for livsstilsdemens.
|
|
Ingen inngripen: Part 3: Control
Participants randomized to this group will receive standard care during their participation
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Dementia Knowledge
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
|
Dementia Knowledge Assessment Tool was designed to measure change in knowledge of dementia including dementia and its progress, support, and care.
It contains 21 true/false items (higher score indicates greater dementia knowledge).
|
Baseline (Week 0) and post-intervention (Month 3)
|
|
Acceptability of Study Program
Tidsramme: Post-intervention (Month 3)
|
Defined by participation rate of 80% or greater in intervention (higher number indicates greater acceptability of the program)
|
Post-intervention (Month 3)
|
|
Program Satisfaction
Tidsramme: Post-intervention (Month 3)
|
As assessed by Client Satisfaction Questionnaire (Min-Max 8-32, higher number is greater satisfaction)
|
Post-intervention (Month 3)
|
|
Epilepsy Self-Management
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
|
Use of epilepsy self-management practices will be assessed with the Epilepsy Self-Management Scale (Min-Max 38-190, higher score means more frequent use of self-management strategies).
|
Baseline (Week 0) and post-intervention (Month 3)
|
|
Attitudes about Aging
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
|
As measured by the Attitudes about Aging questionnaire (3 subscales with Min-Max 8-40; for two subscales, higher score mean more positive attitude; and for the third subscale, higher score means more negative attitude)
|
Baseline (Week 0) and post-intervention (Month 3)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Health literacy
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
|
Assessment of participants' health literacy will be done by the Short Assessment of Health Literacy-English (Min-Max 0-18, lower number indicates lower health literacy)
|
Baseline (Week 0) and post-intervention (Month 3)
|
|
Participant's Quality of life
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
|
As assessed by Quality of life in Epilepsy-31 (raw scores are converted to T-scores and higher T-scores indicate better quality of life) and the Quality of Life in Neurological Disorders (Likert scale format ranging from "Never" to "Always").
|
Baseline (Week 0) and post-intervention (Month 3)
|
|
Participant's confidence in managing different aspects of health
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
|
As measured by the Chronic Disease Self-Efficacy Scale (contains 10 subscales where the score for each scale is the mean of the items, higher numbers indicate higher self-efficacy)
|
Baseline (Week 0) and post-intervention (Month 3)
|
|
Participant's Mood
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
|
As measured by Geriatric Anxiety Inventory (Min-Max 0-20, higher scores indicate greater number of reported anxiety symptoms) and Geriatric Depression Scale (Min-Max 0-15, higher score indicates more depression symptoms)
|
Baseline (Week 0) and post-intervention (Month 3)
|
|
Cognitive Function
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
|
As measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (raw scores are converted to scaled scores to adjust for age, higher scores indicate better performance), the Trail Making Test (measured by total time of completion with higher scores indicating poorer performance), the Test of Practical Judgment (raw scores converted to z-scores based on normative sample, lower z-scores indicating loss of everyday judgment abilities), the Everyday Cognition (scored by on four-point scale, higher total score indicates greater subjective decline in cognitive function), and the Functional Assessment Questionnaire (Min-Max 0-30, higher scores indicate greater impairment in activities of daily living)
|
Baseline (Week 0) and post-intervention (Month 3)
|
|
Sleep quality
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
|
Measured with the Pittsburgh Sleep Quality Index (PSQI).
The PSQI measures the quality and patterns of sleep in older adults.
A global score is generated ranging from 0 to 21, with total score higher than 5 indicating "poor" sleeper.
|
Baseline (Week 0) and post-intervention (Month 3)
|
|
Health-promoting behaviors
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
|
Health promoting behaviors will be measured with the Health-Promoting Lifestyle Profile II (HPLP-II).
The HPLP-II is a 52-item behavior rating scale employs a 4-point response format to measure the frequency of self-reported health-promoting behaviors in the domains of health responsibility, physical activity, nutrition, spiritual growth, interpersonal relations and stress management.
A total score is generating by averaging across all 52 items with higher scores indicating higher number of health-promoting behaviors.
Six subscales are also generated by averaging across the items for each subscale.
|
Baseline (Week 0) and post-intervention (Month 3)
|
|
Cognitive screening
Tidsramme: Baseline
|
The Telephone Montreal Cognitive Assessment (T-MoCA) will be used as screening tool of cognition; the T-MoCA is a modified version of the MoCA-30 that can be administered by phone and measures global cognitive functioning.
Raw scores range from 0 to 22 with higher scores indicating better performance.
|
Baseline
|
|
Alcohol and smoking history
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
|
Information on alcohol use including frequency and types of alcohol consumed and smoking status, amount of smoking, and age at smoking cessation will also be collected.
|
Baseline (Week 0) and post-intervention (Month 3)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Participant clinical and demographic characteristics
Tidsramme: Baseline
|
Participant age, gender, race, ethnicity, marital status, education level, primary language, and working status/profession will be collected of all participants.
Epilepsy clinical history including age of onset, medications, seizure frequency, history and type of surgery, injury related to and seizures.
Other medical and psychiatric history including hypertension, diabetes, hyperlipidemia, mood disorders (depression, anxiety), and family history of dementia.
|
Baseline
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Anny Reyes, PhD, The Cleveland Clinic
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
25. mars 2026
Primær fullføring (Antatt)
31. juli 2030
Studiet fullført (Antatt)
1. august 2030
Datoer for studieregistrering
Først innsendt
18. september 2023
Først innsendt som oppfylte QC-kriteriene
18. september 2023
Først lagt ut (Faktiske)
25. september 2023
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
12. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
10. juni 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB 25-598
- 1K23NS138682-01A1 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-planbeskrivelse
De-identified individual participant data to be shared will include clinical and demographic information, quantitative survey responses, self-report and cognitive assessment data, and summaries of focus group discussions with stakeholder recommendations, along with associated documentation such as codebooks and analytic materials to support interpretation and reuse.
IPD-delingstidsramme
Beginning within the first year after study completion (August 2030) with no end date.
Tilgangskriterier for IPD-deling
IPD and supporting information will be accessible to the general public, who will be able to obtain de-identified participant data and relevant documentation through open, unrestricted access on a public data-sharing platform.
IPD-deling Støtteinformasjonstype
- SEVJE
- ICF
- ANALYTIC_CODE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .